Champions Oncology
CSBR
22 hedge funds and large institutions have $28.2M invested in Champions Oncology in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 3 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0.07% more ownership
Funds ownership: 42.49% → 42.56% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 23 → 22 (-1)
6% less capital invested
Capital invested by funds: $29.9M → $28.2M (-$1.69M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $73K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
+$96.5K |
| 2 |
Morgan Stanley
New York
|
+$68.9K |
| 3 |
Millennium Management
New York
|
+$50.5K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$23.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$98K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$56.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$52.8K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$13.6K |
| 5 |
Renaissance Technologies
New York
|
-$12.2K |
CSBR Hedge Fund Activity: Q3 2024 in Review
22 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q3 2024, worth a combined $28.2M — down 5.6% from $29.9M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CSBR and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 8 added.
The largest buyer was Tocqueville Asset Management, adding an estimated $96.5K. The largest seller was Goldman Sachs, cutting an estimated $98K.
- 22 institutional investors held Champions Oncology (CSBR) as of Q3 2024, down from 23 in Q2 2024.
- Funds reported $28.2M of Champions Oncology stock for Q3 2024, down 5.6% quarter-over-quarter.
- 2 funds opened new Champions Oncology positions in Q3 2024 and 3 closed out, a net change of -1 holder.
- The largest Champions Oncology buyer in Q3 2024 was Tocqueville Asset Management, an estimated $96.5K added.
- The largest Champions Oncology seller in Q3 2024 was Goldman Sachs, an estimated $98K sold.
Based on aggregated 13F filings for Q3 2024.